Antipsychotic use appears to increase mortality risk among older adults with dementia. Whether this risk is similar for regular or intermittent use is unknown. This scoping review aims to explore the temporal association between antipsychotic use and mortality risk for older institutionalized adults.. To read the full article, log in using your NHS Athens details. To access full-text: click “Log in/Register” (top right hand side). Click ‘Institutional Login’ then select 'OpenAthens Federation', then ‘NHS England’. Enter your Athens details to view the article.
From 1 April 2019 pregabalin and gabapentin will be reclassified as class C controlled substances in the UK. The change, announced in October 2018, is expected to prompt a decline in the use of the drugs as prescribing, dispensing, and collecting them becomes more onerous for doctors, pharmacists, and patients. To read the full article, log in using your NHS OpenAthens details.
One of the most exciting recent breakthroughs from research funded by the National Institute of Mental Health, or NIMH, is the development of a fast-acting medication for treatment-resistant depression based on ketamine
Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.
To evaluate the effects of once‐daily valbenazine (40 or 80 mg/day) in older and younger adults with tardive dyskinesia (TD).. To read the full article, log in using your MPFT NHS OpenAthens details.
Editorial. This issue of the Journal is organized around articles that present findings relevant to the development of new pharmacological strategies for the treatment of our patients. As we know, there is a great need for us to discover new treatments as well as to develop novel treatment strategies with compounds that are already available. Unfortunately, our current treatments are limited in scope and efficacy and are targeted toward only a handful of neurotransmitter systems. That said, it is important to emphasize that we have had some recent successes, which include the approval of esketamine for treatment-resistant depression and brexanolone for postpartum depression. In this issue, we are fortunate to have Dr. Joshua Gordon, director of the National Institute of Mental Health (NIMH), contribute an overview that presents his perspective and the NIMH vision regarding the development of new therapeutic strategies for psychiatric patients. . Login at top right hand side of page using your MPFT NHS OpenAthens for full text.
Although U.K. and international guidelines recommend monotherapy, antipsychotic polypharmacy among patients with serious mental illness is common in clinical practice. However, empirical evidence on its effectiveness is scarce. Therefore, the authors estimated the effectiveness of antipsychotic polypharmacy relative to monotherapy in terms of health care utilization and mortality.. Please contact the library to request a copy of this article - http://bit.ly/2HjNDf3
Samuele Cortese on psychosis ADHD, a recent study that looks at the comparative risk of psychosis during treatment with methylphenidate and amphetamines.
Correspondence. Recently, intranasal esketamine spray (Spravato®) was approved by the Food and Drug Administration in the United States of America for its use in treatment‐resistant depression (TRD), after clinical trials demonstrating its antidepressant efficacy and positive effects on suicidal ideation1. The antidepressant mechanisms of action of ketamine‐related molecules, ethical implications, and long‐term safety issues should be addressed.. To read the full article, log in using your NHS Athens details. To access full-text: click “Log in/Register” (top right hand side). Click ‘Institutional Login’ then select 'OpenAthens Federation', then ‘NHS England’. Enter your Athens details to view the article.
Letter. . SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Extended-release naltrexone (XR-NTX), a μ-opioid receptor antagonist for prevention of relapse to opioid dependence, has demonstrated efficacy compared with placebo and comparative effectiveness with buprenorphine-naloxone. We report outcomes for XR-NTX in Vivitrol's Cost and Treatment Outcomes Registry.. Please contact the library to request a copy of this article - http://bit.ly/1Xyazai
Although antidepressant drugs are commonly effective, several meta-analyses of antidepressant drug trials undertaken decades after their introduction suggested that they were effectively acting as placebos. A recent meta-analysis concluded that they were effective. Both conclusions have been widely taken up by the media. This paper seeks to explain the disconnect.. To read the full article, log in using your MPFT NHS OpenAthens details. SSOTP (legacy account) - You can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
computerised interventions have been suggested as an effective strategy to reduce potentially inappropriate prescribing (PIP) for hospitalised older adults. This systematic review and meta-analysis examined the evidence for efficacy of computerised interventions designed to reduce PIP in this patient group.. To read the full article, log in using your MPFT NHS OpenAthens details.
Activation is a behavioral adverse event related to the use of psychotropic medication. Its high incidence in pediatrics and in childhood-onset neuropsychiatric disorders suggests it may be linked to neurodevelopment. However, previous studies have scarcely examined the role that factors relevant to developmental pharmacokinetics, such as body weight, may play in the onset of activation in children and adolescents.. MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
Amlodipine (AMLO) and ramipril (RAMI) belong to the most prescribed drugs in patients with hypertension, a condition also encountered in depression. Venlafaxine may worsen hypertension because of noradrenergic properties. Although of special clinical relevance, data on pharmacokinetic interactions between AMLO, RAMI, and venlafaxine (VEN) are lacking.. MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.
It is unclear how youth treated with antipsychotics are monitored. The purpose of this study was to assess monitoring of metabolic, cardiac, and endocrine indicators in youth (<18 years old) treated with antipsychotics as reported by health care professionals in the Netherlands.. MPFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.